SG
AEON icon

StoneX Group’s AEON Biopharma AEON Stock Holding History

StoneX Group’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Buy
+18,953
New +$15.8K ﹤0.01% 1335
2025
Q4 		– Sell
-17,578
Closed -$14.2K – 1090
2025
Q3 		$14.2K Buy
+17,578
New +$13.5K ﹤0.01% 892

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

StoneX Group's AEON Position: Q2 2026 in Review

StoneX Group opened a new position in AEON Biopharma (AEON) in Q2 2026: 18,953 shares worth $14.9K. The stake represents ﹤0.01% of the portfolio and ranks #1335 among its holdings. This is a return to the name: StoneX Group previously reported a position in AEON as recently as Q3 2025.

StoneX Group first reported a position in AEON in Q3 2025 and has held it in 2 quarters since. 22 funds tracked by Wall St. Rank hold AEON as of Q2 2026.

  • StoneX Group held 18,953 shares of AEON Biopharma worth $14.9K as of Q2 2026.
  • AEON Biopharma was a new StoneX Group position in Q2 2026.
  • AEON Biopharma made up ﹤0.01% of StoneX Group's portfolio in Q2 2026, its #1335 holding.
  • StoneX Group first reported a position in AEON Biopharma in Q3 2025 and has held it in 2 quarters since.
  • 22 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.